Novartis AG (NVSEF)
| Market Cap | 257.26B |
| Revenue (ttm) | 55.19B |
| Net Income (ttm) | 13.65B |
| Shares Out | n/a |
| EPS (ttm) | 6.85 |
| PE Ratio | 18.84 |
| Forward PE | 15.11 |
| Dividend | 3.97 (3.00%) |
| Ex-Dividend Date | Mar 11, 2025 |
| Volume | 392 |
| Average Volume | 37,872 |
| Open | 137.39 |
| Previous Close | 128.77 |
| Day's Range | 127.10 - 137.39 |
| 52-Week Range | 94.70 - 137.39 |
| Beta | 0.56 |
| RSI | 54.43 |
| Earnings Date | Oct 28, 2025 |
About Novartis AG
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocy... [Read more]
Financial Performance
In 2024, Novartis AG's revenue was $51.72 billion, an increase of 10.85% compared to the previous year's $46.66 billion. Earnings were $11.94 billion, a decrease of -19.59%.
Financial StatementsNews
Novartis (NVO) Streamlines Operations with Layoffs in the US
Novartis (NVO) Streamlines Operations with Layoffs in the US
My Top 5 Biotech Stocks Big Pharma Could Buy Next
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of ...
3 Reasons Growth Investors Will Love Novartis (NVS)
Novartis (NVS) could produce exceptional returns because of its solid growth attributes.
Why Novartis (NVS) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
NVS Named Top 10 SAFE International Dividend Stock
Novartis (Symbol: NVS) has been named to the Dividend Channel ''International S.A.F.E. 10'' list, signifying an international stock with above-average ''DividendRank'' statistics including a strong 3....
Novartis: Superstars Entresto And Kisqali Fuel Market Outperformance
Novartis AG (NVS) Hit a 52 Week High, Can the Run Continue?
Novartis (NVS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Swiss pharma companies eye follow up to Pfizer-US pricing deal, business lobby says
GENEVA (Reuters) -Swiss drugmakers could strike their own deals with the U.S. after President Donald Trump's push to lower prescription drug prices led to an accord with Pfizer in exchange for tariff ...
Big pharma is at war with the UK, and the government can’t back down now | Nick Dearden
The industry has always wanted the NHS to pay more for its drugs; now it is pulling research and investment out of Britain This year so far, some of the biggest pharmaceutical corporations in the worl...
FDA Approves Novartis' Rhapsido As First BTKi Oral Therapy For Chronic Spontaneous Urticaria
(RTTNews) - Novartis (NVS) announced that the U.S. Food and Drug Administration has approved Rhapsido (remibrutinib) as an oral treatment for adults with chronic spontaneous urticaria or CSU who conti...
Novartis (NVS) Gains FDA Approval for Innovative CSU Treatment
Novartis (NVS) Gains FDA Approval for Innovative CSU Treatment
Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)
Rhapsido helps to inhibit release of histamine and proinflammatory mediators by targeting BTK, offering unique approach to CSU treatment 1 Well-controlled disease observed as fast as two weeks, with d...
Novartis wins FDA approval of BTK inhibitor remibrutinib for urticaria
FDA approves Novartis' Rhapsido, the first oral BTK inhibitor for chronic spontaneous urticaria. Read more here.
US FDA approves Novartis' drug for skin disease
The U.S. Food and Drug Administration has approved Novartis' oral treatment for patients with type of chronic inflammatory skin disease, the company said on Tuesday.
Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)
Ad hoc announcement pursuant to Art. 53 LR Rhapsido helps to inhibit release of histamine and proinflammatory mediators by targeting BTK, offering unique approach to CSU treatment 1 Well-controlled di...
Pharma's Direct-To-Patient Wave Hits Novartis Next
The Pharmaceutical Research and Manufacturers of America (PhRMA) outlined initiatives to bolster U.S. manufacturing, ease patient costs, and improve access to medicine . The trade group emphasized tha...
Novartis to Launch Direct-to-Patient Platform for Cosentyx in U.S.
The company is the latest pharma giant to move on price-cutting ahead of the Trump administration's deadline.
Novartis to Launch Direct-to-Patient Platform for Cosentyx® (secukinumab) in the US
Basel, September 29, 2025 – Today, Novartis announced plans to launch a direct-to-patient (DTP) platform in the US which will come into effect on November 1, 2025, offering cash-paying patients prescr...
Novartis announces commencement of tender offer to acquire Tourmaline Bio
Basel, September 29, 2025 - Novartis today announced that Torino Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Purchaser”), has commenced a tender offer...
Amneal seeks FDA nod for generic targeting Xolair marketed by Roche and Novartis
Trump's Tariffs Impact Novartis (NVS) and Other Drugmakers
Trump's Tariffs Impact Novartis (NVS) and Other Drugmakers
Novartis to showcase transformative data in advanced prostate and early breast cancer at ESMO 2025
Basel, September 26, 2025 – Novartis will present new data from 34 abstracts across its oncology portfolio at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin (October 17-21, 2...
DFIV, B, TD, NVS: Large Inflows Detected at ETF
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Dimensional International Value ETF (Symbol: DFIV) where we have detec...
New Novartis data further support benefits of Kesimpta® in relapsing MS following switch from oral disease modifying therapies
Basel, September 24, 2025 – Novartis today announced new data from two Kesimpta® (ofatumumab) studies in relapsing multiple sclerosis (RMS) that will be presented at the European Committee for Treatme...
A Nobel Prize? How Big Pharma is trying to appease Trump
Novartis' CEO said his company was working with the US 'on eliminating the price gap between the US and other industrialised countries'